for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Imugene Limited

IMU.AX

Latest Trade

0.48AUD

Change

0.00(0.00%)

Volume

14,250,980

Today's Range

0.46

 - 

0.48

52 Week Range

0.05

 - 

0.52

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.48
Open
0.48
Volume
14,250,980
3M AVG Volume
553.58
Today's High
0.48
Today's Low
0.46
52 Week High
0.52
52 Week Low
0.05
Shares Out (MIL)
4,962.84
Market Cap (MIL)
2,610.03
Forward P/E
-105.56
Dividend (Yield %)
--

Next Event

Imugene Ltd Annual Shareholders Meeting

Latest Developments

更多

Imugene Ltd Says Patent Granted In Japan For Her-Vaxx Immunotherapy

Imugene Posts FY Loss Of A$18.5 Mln

Imugene Gets FDA Ind Approval Of New Oncolytic Virotherapy Checkvacc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Imugene Limited

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.

Industry

Biotechnology & Drugs

Contact Info

37 Bligh Street, Suite 1006, Level 10

SYDNEY, NSW

2000

Australia

+61.3.98245254

http://www.imugene.com/

Executive Leadership

Paul E. Hopper

Executive Chairman of the Board

Leslie Chong

Chief Executive Officer, Managing Director

Ursula Wiedermann

Chief Scientific Officer

Rita Laeufle

Chief Medical Officer

Monil Shah

Chief Business Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (AUD)

2019

-0.002

2020

-0.003

2021

-0.004

2022(E)

-0.005
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
36.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.42
LT Debt To Equity (MRQ)
0.25
Return on Investment (TTM)
-28.47
Return on Equity (TTM)
-26.94

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up